Single-Arm Study to Assess the Efficacy of UVADEX® (Methoxsalen) Sterile Solution in Conjunction With the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients With Steroid-Refractory Acute Graft-vs-Host Disease (aGvHD)

Trial Profile

Single-Arm Study to Assess the Efficacy of UVADEX® (Methoxsalen) Sterile Solution in Conjunction With the THERAKOS® CELLEX® Photopheresis System in Pediatric Patients With Steroid-Refractory Acute Graft-vs-Host Disease (aGvHD)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2017

At a glance

  • Drugs Methoxsalen (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Sponsors Mallinckrodt Inc.; Therakos
  • Most Recent Events

    • 22 Sep 2017 Planned End Date changed from 1 Nov 2018 to 1 Oct 2018.
    • 12 May 2016 Planned End Date changed from 1 May 2017 to 1 Nov 2018.
    • 12 May 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Oct 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top